[{"address1": "12770 High Bluff Drive", "address2": "Suite 150", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "(619) 949-3681", "website": "https://www.gyretx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.", "fullTimeEmployees": 579, "companyOfficers": [{"maxAge": 1, "name": "Dr. Han  Ying Ph.D.", "age": 58, "title": "CEO & Director", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 397945, "exercisedValue": 0, "unexercisedValue": 3216}, {"maxAge": 1, "name": "Mr. Songjiang  Ma", "age": 68, "title": "President & Director", "yearBorn": 1956, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruoyu  Chen", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 285000, "exercisedValue": 0, "unexercisedValue": 6744174}, {"maxAge": 1, "name": "Mr. Weiguo  Ye", "age": 46, "title": "Chief Operating Officer", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 332619, "exercisedValue": 0, "unexercisedValue": 18899056}, {"maxAge": 1, "name": "Mr. Ping  Zhang", "age": 51, "title": "Executive Chair", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 10.94, "open": 10.99, "dayLow": 10.99, "dayHigh": 11.67, "regularMarketPreviousClose": 10.94, "regularMarketOpen": 10.99, "regularMarketDayLow": 10.99, "regularMarketDayHigh": 11.67, "payoutRatio": 0.0, "trailingPE": 567.50006, "forwardPE": 24.673914, "volume": 134954, "regularMarketVolume": 134954, "averageVolume": 157741, "averageVolume10days": 120360, "averageDailyVolume10Day": 120360, "bid": 11.29, "ask": 11.48, "bidSize": 1, "askSize": 1, "marketCap": 999946368, "fiftyTwoWeekLow": 6.11, "fiftyTwoWeekHigh": 19.0, "priceToSalesTrailing12Months": 9.935578, "fiftyDayAverage": 9.225, "twoHundredDayAverage": 11.5213, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1007819840, "profitMargins": 0.07205, "floatShares": 17764694, "sharesOutstanding": 88101000, "sharesShort": 2367978, "sharesShortPriorMonth": 2387452, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.0253, "heldPercentInsiders": 0.84998, "heldPercentInstitutions": 0.02812, "shortRatio": 14.04, "shortPercentOfFloat": 0.1346, "impliedSharesOutstanding": 88101000, "bookValue": 0.777, "priceToBook": 14.607465, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "earningsQuarterlyGrowth": -0.642, "netIncomeToCommon": 7251000, "trailingEps": 0.02, "forwardEps": 0.46, "lastSplitFactor": "1:15", "lastSplitDate": 1698710400, "enterpriseToRevenue": 10.014, "enterpriseToEbitda": 83.023, "52WeekChange": -0.24185723, "SandP52WeekChange": 0.11469197, "lastDividendValue": 3.6, "lastDividendDate": 1673568000, "quoteType": "EQUITY", "currentPrice": 11.35, "targetHighPrice": 20.0, "targetLowPrice": 20.0, "targetMeanPrice": 20.0, "targetMedianPrice": 20.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 1, "totalCash": 29891000, "totalCashPerShare": 0.339, "ebitda": 12139000, "totalDebt": 1585000, "quickRatio": 2.647, "currentRatio": 3.604, "totalRevenue": 100643000, "debtToEquity": 1.52, "revenuePerShare": 1.172, "returnOnAssets": 0.05178, "returnOnEquity": 0.12117, "grossProfits": 96844000, "freeCashflow": -8549625, "operatingCashflow": -6654000, "earningsGrowth": -0.863, "revenueGrowth": -0.188, "grossMargins": 0.96225, "ebitdaMargins": 0.12061, "operatingMargins": 0.10305, "financialCurrency": "USD", "symbol": "GYRE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Gyre Therapeutics, Inc.", "longName": "Gyre Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1144848600000, "postMarketChangePercent": 0.0, "postMarketPrice": 11.35, "postMarketChange": 0.0, "regularMarketChange": 0.4100008, "regularMarketDayRange": "10.99 - 11.67", "fullExchangeName": "NasdaqCM", "cryptoTradeable": false, "exchange": "NCM", "averageDailyVolume3Month": 157741, "fiftyTwoWeekLowChange": 5.2400002, "fiftyTwoWeekLowChangePercent": 0.8576105, "fiftyTwoWeekRange": "6.11 - 19.0", "fiftyTwoWeekHighChange": -7.6499996, "fiftyTwoWeekHighChangePercent": -0.40263155, "fiftyTwoWeekChangePercent": -24.185722, "dividendDate": 1673481600, "earningsTimestamp": 1739885400, "earningsTimestampStart": 1754915400, "earningsTimestampEnd": 1755261000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 0.02, "epsForward": 0.46, "fiftyDayAverageChange": 2.125, "fiftyDayAverageChangePercent": 0.2303523, "twoHundredDayAverageChange": -0.17129993, "twoHundredDayAverageChangePercent": -0.014868108, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.0 - Strong Buy", "corporateActions": [], "postMarketTime": 1747425908, "regularMarketTime": 1747425601, "messageBoardId": "finmb_100542295", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 3.7477221, "regularMarketPrice": 11.35, "displayName": "Gyre Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-17"}]